STROMECTOL 3 MG
IVERMECTIN : 3 MG · DIN 02480557 · MERCK CANADA INC
Health Canada status: MARKETED

What is STROMECTOL?
STROMECTOL 3 MG contains IVERMECTIN : 3 MG. It is listed in the Health Canada Drug Product Database under DIN 02480557, held by MERCK CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 06-Nov-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is STROMECTOL used for?
STROMECTOL® (ivermectin) is indicated for the treatment of: • intestinal strongyloidiasis; • onchocerciasis;
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02480557 |
|---|---|
| Brand name | STROMECTOL |
| Generic / active ingredient | IVERMECTIN : 3 MG |
| Manufacturer | MERCK CANADA INC |
| Strength | 3 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | P02CF01 IVERMECTIN |
| AHFS class | 08:08.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Nov-2018 |
| Original market date | 2018-11-06 00:00:00 |
How is it administered?
STROMECTOL® is administered as a single oral dose given with water on an empty stomach. Strongyloidiasis: The recommended dosage of STROMECTOL® for the treatment of strongyloidiasis is a single oral dose designed to provide approximately 200 mcg of ivermectin per kg of body weight. Patients should take tablets on an empty stomach with water. In general, additional doses are not necessary. However, follow-up stool examinations should be performed to verify eradication of infection. Onchocerciasis: The recommended dosage of STROMECTOL® for the treatment of onchocerciasis is a single oral dose designed to provide approximately 150 mcg/kg of body weight. Patients should take tablets on an empty stomach with water. In mass distribution campaigns for onchocerciasis, the most commonly used dose interval is 12 months. For the treatment of individual patients, retreatment may be considered at intervals as short as 3 months.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C.
How is it supplied?
STROMECTOL® tablets, 3 mg, are white, round, flat, bevel-edged tablets engraved with MSD on one side and 32 on the other side. They are supplied in unit dose packages in cartons of 4 tablets.
Contraindications
STROMECTOL® is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Do not use STROMECTOL® if there is a history of hypersensitivity reaction to this product. Rarely, patients who are also heavily infected with Loa loa may develop a serious or even fatal encephalopathy either spontaneously or following treatment with an effective microfilaricide. In these patients, the following adverse experiences have also been reported: pain (including neck and back pain), red eye, conjunctival hemorrhage, dyspnea, urinary and/or fecal incontinence, difficulty in standing/walking, mental status changes, confusion, lethargy, stupor, seizures, or coma. This syndrome has been seen very rarely following the use of STROMECTOL®. In individuals who warrant treatment with STROMECTOL® for any reason and have had significant exposure to Loa loa-endemic areas of West or Central Africa, pretreatment assessment for loiasis and careful post-treatment follow-up should be implemented. Neurological toxicity, including depressed level of consciousness and coma, has also been reported in patients with the use of ivermectin in the absence of Loa loa infection. These events have generally resolved with supportive care and the discontinuation of ivermectin. After treatment with microfilaricidal drugs, patients with hyperreactive onchodermatitis (sowda) may be more likely than others to experience severe adverse reactions, especially edema and aggravation of onchodermatitis.
Who else supplies IVERMECTIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IVERMECTIN appears in 37 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.